A new Boston, USA-based company has been launched by PureTech Ventures together with several major pharmaceutical companies. Enlight Biosciences will direct its budget of up to $39.0 million to advance breakthrough technologies that can fundamentally alter drug discovery and development.
The industry players that helped establish the company - US drug majors Merck & Co, Eli Lilly and world drug giant Pfizer - have the opportunity to invest in the development of these technologies. Enlight was co-founded by PureTech Ventures and a group of senior academics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze